Interparfums, Inc. (IPAR)
(Delayed Data from NSDQ)
$121.69 USD
+0.62 (0.51%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $121.49 -0.20 (-0.16%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$121.69 USD
+0.62 (0.51%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $121.49 -0.20 (-0.16%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth D Momentum C VGM
Zacks News
The Estee Lauder (EL) to Raise Stake in DECIEM to Aid Growth
by Zacks Equity Research
The Estee Lauder (EL) will increase its stake in DECIEM from nearly 29% to roughly 76% for almost $1 billion. The deal is likely to be concluded during the quarter ending Jun 30.
4 Factors That Make The Estee Lauder (EL) a Promising Pick
by Zacks Equity Research
The Estee Lauder's (EL) impressive online business is driving growth. Also, the company's Skin Care portfolio is performing well.
Inter Parfums (IPAR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Inter Parfums (IPAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nu Skin (NUS) Tops Q4 Earnings Estimates, Raises Dividend
by Zacks Equity Research
Growth in sales leaders and customer base drove Nu Skin's (NUS) fourth-quarter 2020 results. Notably, earnings and revenues increased year over year.
Estee Lauder (EL) Q2 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
Estee Lauder's (EL) second-quarter fiscal 2021 sales and earnings increase year over year. However, results reflect impact of some retail store closures and lower traffic in reopened stores amid COVID-19.
Clorox (CLX) Q2 Earnings, Sales Top Estimates on Strong Demand
by Zacks Equity Research
Clorox's (CLX) Q2 sales benefit from double-digit sales growth in the majority of the segments, fueled by strong product demand due to the coronavirus outbreak and related shift in trends.
Inter Parfums (IPAR) Ups 2020 Earnings View on Solid Q4 Sales
by Zacks Equity Research
Inter Parfums' (IPAR) sales increase year over year in fourth-quarter 2020. Management raises 2020 earnings guidance.
Inter Parfums' (IPAR) Subsidiary to Buy Office Building Complex
by Zacks Equity Research
Inter Parfums' (IPAR) subsidiary Interparfums SA to buy property in Paris, which will be used as its headquarters. Management expects to close the transaction during spring of 2021.
Inter Parfums (IPAR) Up 3.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Inter Parfums (IPAR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inter Parfums (IPAR) Offers 2021 View, Product Launches on Track
by Vrishali Bagree
Inter Parfums' (IPAR) 2021 guidance indicates sales and earnings growth. The company is set to strengthen its brand portfolio through product introductions in 2021.
Estee Lauder (EL) Gains on Solid Online Business & Savings
by Zacks Equity Research
Estee Lauder (EL) is benefiting from its robust e-commerce business, especially amid the COVID-19 outbreak. Also, its solid presence in emerging markets is impressive.
Nu Skin (NUS) Looks Radiant on Innovation & Digital Strength
by Zacks Equity Research
Nu Skin (NUS) has been gaining on initiatives to strengthen sales leader and expand customer base through product launches. Also, the company's focus on digital operations bodes well.
Is Colgate (CL) Benefiting From Healthy Consumer Good Demand?
by Zacks Equity Research
Colgate (CL) benefits from the increase in demand for personal and home care products due to the pandemic-led increase in hygiene habits.
Earnings Estimates Moving Higher for Inter Parfums (IPAR): Time to Buy?
by Zacks Equity Research
Inter Parfums (IPAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Inter Parfums (IPAR) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Inter Parfums (IPAR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Inter Parfums (IPAR) Q3 Earnings Beat Estimates, Sales Down
by Zacks Equity Research
Inter Parfums' (IPAR) third-quarter 2020 sales and earnings fall year over year. Nevertheless, results reflect sequential growth as stores reopened and e-commerce business was robust.
Inter Parfums (IPAR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Inter Parfums (IPAR) delivered earnings and revenue surprises of 26.83% and 0.02%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Inter Parfums (IPAR) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Adverse impacts stemming from lack of new product launches in 2020 is likely to get reflected in Inter Parfums' (IPAR) third-quarter 2020 sales.
Why Inter Parfums (IPAR) Might Surprise This Earnings Season
by Zacks Equity Research
Inter Parfums (IPAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Nu Skin (NUS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Continued investment in digital capabilities and benefits from robust product portfolio are likely to get reflected in Nu Skin's (NUS) third-quarter 2020 performance.
Inter Parfums (IPAR) Raises 2020 View Despite Soft Q3 Sales
by Zacks Equity Research
Inter Parfums' (IPAR) sales decline year over year across all geographies in third-quarter 2020. Nevertheless, better-than-expected rebound leads management to raise 2020 view.
Simple Market Timing Strategies That Work - September 14, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Zacks Industry Outlook Highlights: Helen of Troy, Nu Skin, Inter Parfums, e.l.f. Beauty and Estee Lauder
by Zacks Equity Research
Zacks Industry Outlook Highlights: Helen of Troy, Nu Skin, Inter Parfums, e.l.f. Beauty and Estee Lauder
4 Cosmetics Stocks to Buff Up Your Portfolio Amid Industry Challenges
by Zacks Equity Research
The Zacks Cosmetics industry is facing COVID-19 woes like disturbed travel retail, low traffic and soft makeup demand. Rising demand for personal care products however bodes well for HELE, NUS, IPAR and ELF, which are focused on adapting to the changing market trends.
Inter Parfums Down on 2020 View, Travel Retail Woes to Stay
by Zacks Equity Research
Inter Parfums (IPAR) expects net sales of roughly $442 million for 2020, indicating a decline from 2019 levels. Travel retail is likely to remain under pressure.